EXELIXIS INC's ticker is EXEL and the CUSIP is 30161Q104. A total of 323 filers reported holding EXELIXIS INC in Q3 2018. The put-call ratio across all filers is 0.34 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $1,384,242 | -3.2% | 61,604 | +2.3% | 0.01% | 0.0% |
Q1 2024 | $1,429,495 | -1.1% | 60,240 | 0.0% | 0.01% | -16.7% |
Q4 2023 | $1,445,158 | +19.7% | 60,240 | +9.0% | 0.01% | +20.0% |
Q3 2023 | $1,207,125 | +21.5% | 55,246 | +6.2% | 0.01% | +25.0% |
Q2 2023 | $993,816 | +7.4% | 52,005 | +9.1% | 0.00% | -20.0% |
Q1 2023 | $925,236 | +26.2% | 47,668 | +4.3% | 0.01% | +25.0% |
Q4 2022 | $733,253 | +9.3% | 45,714 | +6.8% | 0.00% | 0.0% |
Q3 2022 | $671,000 | -20.3% | 42,787 | +5.8% | 0.00% | -20.0% |
Q2 2022 | $842,000 | -13.0% | 40,434 | -5.3% | 0.01% | 0.0% |
Q1 2022 | $968,000 | +21.3% | 42,697 | -2.2% | 0.01% | +25.0% |
Q4 2021 | $798,000 | +13.4% | 43,639 | +31.0% | 0.00% | 0.0% |
Q3 2021 | $704,000 | +19.1% | 33,312 | +2.8% | 0.00% | +33.3% |
Q2 2021 | $591,000 | -23.6% | 32,416 | -5.4% | 0.00% | -40.0% |
Q1 2021 | $774,000 | +2.2% | 34,263 | -9.1% | 0.01% | 0.0% |
Q4 2020 | $757,000 | -8.9% | 37,699 | +10.9% | 0.01% | -16.7% |
Q3 2020 | $831,000 | +3.0% | 33,994 | 0.0% | 0.01% | -14.3% |
Q2 2020 | $807,000 | +75.1% | 33,994 | +26.9% | 0.01% | +75.0% |
Q1 2020 | $461,000 | +27.7% | 26,784 | +30.7% | 0.00% | +33.3% |
Q4 2019 | $361,000 | +5.9% | 20,495 | +6.4% | 0.00% | 0.0% |
Q3 2019 | $341,000 | -12.3% | 19,259 | +5.9% | 0.00% | 0.0% |
Q2 2019 | $389,000 | -20.8% | 18,190 | -11.9% | 0.00% | -25.0% |
Q1 2019 | $491,000 | +4.0% | 20,642 | -14.0% | 0.00% | -20.0% |
Q4 2018 | $472,000 | +18.3% | 24,006 | +6.7% | 0.01% | +66.7% |
Q3 2018 | $399,000 | -11.5% | 22,509 | +7.4% | 0.00% | -25.0% |
Q2 2018 | $451,000 | -2.8% | 20,961 | 0.0% | 0.00% | 0.0% |
Q1 2018 | $464,000 | -27.4% | 20,961 | -0.3% | 0.00% | -33.3% |
Q4 2017 | $639,000 | +62.6% | 21,019 | +29.8% | 0.01% | +50.0% |
Q3 2017 | $393,000 | +44.5% | 16,199 | +46.6% | 0.00% | +33.3% |
Q2 2017 | $272,000 | -15.0% | 11,053 | -25.1% | 0.00% | 0.0% |
Q1 2017 | $320,000 | +65.8% | 14,751 | +14.2% | 0.00% | +50.0% |
Q4 2016 | $193,000 | +69.3% | 12,913 | +44.3% | 0.00% | +100.0% |
Q3 2016 | $114,000 | +192.3% | 8,948 | +78.3% | 0.00% | 0.0% |
Q2 2016 | $39,000 | +95.0% | 5,019 | 0.0% | 0.00% | – |
Q1 2016 | $20,000 | -28.6% | 5,019 | 0.0% | 0.00% | – |
Q4 2015 | $28,000 | +100.0% | 5,019 | +99.3% | 0.00% | – |
Q3 2015 | $14,000 | -98.6% | 2,518 | -99.2% | 0.00% | -100.0% |
Q2 2014 | $1,017,000 | +14.9% | 300,000 | +20.0% | 0.03% | +11.1% |
Q1 2014 | $885,000 | +52.1% | 250,000 | +150.0% | 0.03% | +35.0% |
Q3 2013 | $582,000 | +42.3% | 100,000 | +11.1% | 0.02% | +42.9% |
Q2 2013 | $409,000 | -1.7% | 90,000 | 0.0% | 0.01% | -6.7% |
Q1 2013 | $416,000 | -56.3% | 90,000 | -56.7% | 0.02% | -59.5% |
Q4 2012 | $951,000 | -5.2% | 208,000 | 0.0% | 0.04% | -9.8% |
Q3 2012 | $1,003,000 | -9.3% | 208,000 | +4.0% | 0.04% | -18.0% |
Q2 2012 | $1,106,000 | -21.1% | 200,000 | -26.0% | 0.05% | -20.6% |
Q1 2012 | $1,401,000 | +167.9% | 270,400 | +144.9% | 0.06% | +162.5% |
Q4 2011 | $523,000 | – | 110,400 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Meditor Group Ltd | 15,001,073 | $320,572,000 | 64.48% |
Sargent Investment Group, LLC | 432,125 | $9,235,000 | 4.22% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 443,534 | $9,483,000 | 3.52% |
Bellevue Group AG | 3,878,800 | $82,890,000 | 1.42% |
CAPITAL MANAGEMENT CORP /VA | 237,855 | $5,083,000 | 1.40% |
Orbimed Advisors | 3,912,900 | $83,619,000 | 1.30% |
Portolan Capital Management | 540,590 | $11,552,000 | 1.24% |
TEALWOOD ASSET MANAGEMENT INC | 139,347 | $2,978,000 | 1.21% |
Signition LP | 84,120 | $1,798,000,000 | 1.18% |
Penn Capital Management Company, LLC | 529,630 | $11,318,000 | 1.12% |